JFrog stock rises as Cantor Fitzgerald maintains Overweight rating after strong Q2
Silence Therapeutics plc (NASDAQ:SLN) announced that Michael Davidson resigned from its board of directors on Monday, effective immediately. According to a statement in the company’s SEC filing, Dr. Davidson also stepped down from his roles on the Audit and Risk Committee, Remuneration Committee, and Science & Technology Committee.
The company reported that Dr. Davidson’s decision was made to focus on his other professional commitments, including his position as Chief Executive Officer of NewAmsterdam Pharma Company N.V. The filing stated that his resignation was not due to any disagreement with Silence Therapeutics, its management, or the board.
Following Dr. Davidson’s departure, the board reduced its number of directors from five to four. The board also appointed Iain Ross, who serves as chairman, to the Audit and Risk Committee to fill the vacancy left by Dr. Davidson.
This information is based on a press release statement included in the company’s recent SEC filing. Silence Therapeutics plc’s American Depositary Shares are listed on the Nasdaq Stock Market under the symbol SLN.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.